DOCSLIB.ORG

Fagron Industry Foreword Fagron Worldwide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fagron Industry Foreword Fagron Worldwide Fagron Industry Foreword Fagron worldwide Fagron provides the best in innovation, Fagron is fully compliant with the Falsified solutions and quality and has been able to Medicines Directive. In force since 2 July secure an exclusive position in everyday 2013, this requires written authentication to healthcare. This allows our customers to accompany each import of an API from a EUROPE adequately respond to the growing country outside the EU and ensures patient USA 8 sites worldwide need for tailor-made medication. safety and controlled trading. We only 3 sites GMP, FDA, ISO9001 approve suppliers that have successfully GMP, FDA Our extensive range of innovative vehicles completed the Fagron Group Supplier developed by Fagron R&D and over 5,000 Qualification process, including on-site Active Pharmaceutical Ingredients (APIs), audits. excipients, inflammables and herbs are daily CHINA In only 20 years, Fagron developed from a accessible, globally for the pharmaceutical, Over 160 Fagron pharmacists are continually purchase & local player to become the global market veterinary, food, nutraceutical and cosmetic developing new, unique products and quality office leader for specialised pharmaceutical industries. Our offer also includes an concepts to meet the growing worldwide solutions. With over 1,500 employees extensive range of other products, such as demand for tailor-made medication. We are active in 60 countries worldwide, Fagron packaging materials, capsules, appliances, a R&D scientific company that is fully provides over 200,000 customers balances and miscellaneous laboratory committed to optimisation and innovation worldwide with high-quality products, instruments and utilities. With our in pharmaceutical solutions. Our dedicated concepts and solutions. pharmaceutical raw materials, innovative approach has recently led to the BRAZIL vehicles and wide range of services, we not development and introduction of a new and 4 sites only guarantee product quality, but also extensive generation of innovative vehicles GMP, FDA, ISO9001 ensure ease of use. that are introduced globally. We invite you to read about the benefits and qualities of FAGRON GROUP We offer raw material conditioning these new products in the Fagron 5,000 pharmaceutical raw materials according to specific production Innovative Vehicles Flyer. 15 sites requirements, the highest quality raw materials from reputable producers and Fagron, the global market leader for third-party compounding and contract specialised pharmaceutical solutions! manufacturing. All of our activities comply with comprehensive documentation, in line Ger van Jeveren, with current GMP/GDP directives. Founder and CEO Fagron Group From local player to global market leader and Fagron mission consolidator in the market of pharmaceutical and strategy compounding in only 20 years Fagron’s strategy is focused on the optimisation and innovation of Fagron Executive Committee Fagron was founded in Rotterdam (the Netherlands) in 1990 by Ger van Jeveren, the current pharmaceutical compounding. CEO of the Fagron Group. Through a continuous focus on innovation, quality and solution- As a R&D scientific pharmaceutical oriented thinking, Ger van Jeveren brought market leadership in pharmaceutical compounding company, Fagron wants compounding to Fagron in the Netherlands in just 7 years. to widen the therapeutic scope of the prescriber to enable tailor-made Ger van Jeveren continued to direct further development and international growth, with the pharmaceutical care. Through its result that Fagron is currently the global market leader and active in 30 countries in Europe, activities, Fagron supports the unique the Americas, the Middle East, Africa, Asia, and the Pacific. Fagron products are sold over selling point of the pharmacist and Ger van Jeveren Constantijn van Rietschoten Michaël Hillaert Rafael Padilla 200,000 customers in over 60 countries around the world. improves the patient’s quality of life. Founder and CEO Marketing, Innovation and Area Manager Germany, Area Manager South America, Business Development Poland, Nordic, France and Italy and Iberica Market leadership provides major competitive advantages, such as the central procurement Fagron business model Belgium of raw materials, optimal utilisation of production facilities, and the international roll-out of successful and innovative products and concepts. With over 1,500 employees, Fagron generated a turnover of US$ 400 million in 2012. Fagron intends to further reinforce its worldwide market leadership based on an active buy-and-build strategy, starting up greenfields and robust organic growth. Jan Peeters Karin de Jong René Clavaux Erik Hoppenbrouwer Finance Controlling Information Management Operations * Fagron Compounding Services Fagron values Fagron unique added values Our values define what we are and what we Combining the forces raw materials globally while operating close aim to be. They reflect the way we should to the production sites. This results in full operate both internally and externally. of procurement, traceability and a high standard of quality. Our values give us standards to measure manufacturing and On-site producer audits, (re)qualifications ourselves by, particularly in our dealings and regular performance assessments with customers, suppliers, our own people quality management guarantee continuous control of Fagron’s and the wider world. The values have real product portfolio. Securing that meaning for us and the way we behave. More than 200,000 customers worldwide pharmaceutical raw materials quality is in have access to over 5,000 high-quality accordance with the latest editions of pharmaceutical raw materials thanks to worldwide pharmacopoeias, and ensuring We believe in: Fagron’s global product and producer that all pharmaceutical raw materials in • Customer is number 1 qualification, full analysis of incoming and Fagron’s range are produced in factories needs in a manufacturing network that produced products, GMP conditioning and which are inspected by regulatory agencies includes its own production facilities and • Entrepreneurship release by a qualified person. This unique including FDA, EMA and ANVISA, and are contract manufacturers on three continents, • Speed of execution position makes Fagron attractive to GMP-compliant, is essential to Fagron’s being all meeting the latest national and pharmacies, hospitals and the able to guarantee its high quality standards. international standards (GMP and GDP). • Results-driven pharmaceutical, veterinary, food, Pharmaceutical raw materials are subjected Regular audits are performed internally and • Innovation nutraceutical and cosmetic industries. to a rigorous process of tests. The results of by third parties. these tests and the extensive range of • Behave as a global Procurement documents Fagron demands from producers At 15 sites with more than 150 clean rooms, market leader Fagron has sourcing offices in South America, are reviewed by a qualified person before Fagron manufactures creams, syrups, North America, Europe and, in 2012, Fagron products are released. compounded medication and other high opened a sourcing office in Shanghai (China). quality products for pharmaceutical This brings Fagron closer to the world’s Manufacturing purposes. These products come in a wide biggest producers of pharmaceutical raw Fagron produces standardised products as range of packaging including containers, materials so it can source its pharmaceutical well as products tailored to specific customer tubes, bottles, syringes and blisters. Quality management From selecting a producer until delivery of a Fagron product to the customer, Fagron Quality goes through multiple steps as the following table shows. Fagron employs over 160 pharmacists worldwide. Within Quality Management, there are over 140 professionals who maintain and ensure Fagron’s high quality standards. QUALITY TASKS QUALITY TASKS Quality (in coordination with Procurement) Quality (in coordination with Sales) Set up confidentiality agreements with producers Handling complaints Producers qualification Handling recalls Products qualification Audits of producers Quality (in coordination with Production) Quality (general) Incoming product analysis Manage quality system Manage out of specifications Write and implement global procedures Incoming product release Keep site master file Perform and review in-process controls Communication with competent authorities Perform stability testing Host competent authorities’ audits Process validation and calibration Stay updated on new regulations Handling deviations Host audits from customers Manage change control Perform internal audits Implement corrective and preventive actions Provide GMP training Approve labelling Quality helpdesk Review production data and documents and release/reject produced products Product quality review Check and publish MSDS Perform risk assessment Check warehousing Obtain manufacture licences and certificates Check transports (GDP) Set up vendors’ technical agreements To go even further in meeting our customers’ needs, Certificates of Analysis (CoA), Material Safety Data Sheets (MSDS), and technical specifications are available for all our products online (fagron.com) or upon request. Fagron innovative solutions Fagron assortment 100132 Amoxicilline trihydr. G RAW MATERIALS 100133 Amphetamine sulfate (DL-) G 100448 18 Beta Glycyrrhetenic acid G 103703 Amphisol K / Potassium cetylphosphate G 105611 7-Keto DHEA G 100134 Amphotericin B G 102974 Abil® antistatic
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Arxula Adeninivorans
    Biernacki et al. Microb Cell Fact (2017) 16:144 DOI 10.1186/s12934-017-0751-4 Microbial Cell Factories RESEARCH Open Access Enhancement of poly(3‑hydroxybutyrate‑co‑ 3‑hydroxyvalerate) accumulation in Arxula adeninivorans by stabilization of production Mateusz Biernacki1, Marek Marzec1,6, Thomas Roick2, Reinhard Pätz3, Kim Baronian4, Rüdiger Bode5 and Gotthard Kunze1* Abstract Background: In recent years the production of biobased biodegradable plastics has been of interest of research- ers partly due to the accumulation of non-biodegradable plastics in the environment and to the opportunity for new applications. Commonly investigated are the polyhydroxyalkanoates (PHAs) poly(hydroxybutyrate) and poly(hydroxybutyrate-co-hydroxyvalerate) (PHB-V). The latter has the advantage of being tougher and less brittle. The production of these polymers in bacteria is well established but production in yeast may have some advantages, e.g. the ability to use a broad spectrum of industrial by-products as a carbon sources. Results: In this study we increased the synthesis of PHB-V in the non-conventional yeast Arxula adeninivorans by stabilization of polymer accumulation via genetic modifcation and optimization of culture conditions. An A. adenini- vorans strain with overexpressed PHA pathway genes for β-ketothiolase, acetoacetyl-CoA reductase, PHAs synthase and the phasin gene was able to accumulate an unexpectedly high level of polymer. It was found that an opti- 1 mized strain cultivated in a shaking incubator is able to produce up to 52.1% of the DCW of PHB-V (10.8 g L− ) with 12.3%mol of PHV fraction. Although further optimization of cultivation conditions in a fed-batch bioreactor led to lower polymer content (15.3% of the DCW of PHB-V), the PHV fraction and total polymer level increased to 23.1%mol 1 and 11.6 g L− respectively.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Contact Allergy to Aluminium Siemund, Ingrid
    Contact allergy to aluminium Siemund, Ingrid 2017 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Siemund, I. (2017). Contact allergy to aluminium. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 INGRID SIEMUND INGRID Contact allergy to aluminium Contact allergy to aluminium INGRID SIEMUND | DEPARTMENT OF OCCUPATIONAL AND ENVIRONMENTAL DERMATOLOGY | SKÅNE UNIVERSITY HOSPITAL, LUND UNIVERSITY 9 Department of Occupational and 789176 Environmental Dermatology Lund University, Faculty of Medicine 2017:113 Doctoral Dissertation Series 2017:113 194959 ISBN 978-91-7619-495-9 ISSN 1652-8220 Contact allergy to aluminium 1 2 Contact allergy to aluminium Ingrid Siemund DOCTORAL DISSERTATION by due permission of the Faculty of Medicine, Lund University, Sweden.
    [Show full text]
  • Airgid - Instructions for Use Im3 Airgid Is a Gelatin Collagen Sponge of Hemostatic Action to Which 5 % Colloidal Silver Is Added
    Airgid - Instructions for Use iM3 Airgid is a gelatin collagen sponge of hemostatic action to which 5 % colloidal silver is added. It facilitates optimum wound treatment when applied to a surgical cavity and can be cut to the required size to fit smaller wound cavities. The evenly porous foam structure absorbs its own weight in blood several times over, promotes thrombocyte aggregation due to the large surface and fills the wound cavity. The plug thus formed has a constant volume, fits snugly and stabilises blood coagulum. This prevents the formation of fissures and secondary cavities which, without iM3 Airgid, could form by contraction of the blood coagulum and trigger infection due to the invasion of contaminated saliva. Does not block the callus formation. iM3 Airgid remains in the wound and completely absorbed within 3-4 weeks. The addition of colloidal silver has an antimicrobial effect and does not develop any body resistance. Unlike other potential antimicrobial additives, colloidal silver cannot be washed away from the sponge so that its insolubility produces a long-lasting depot effect. Gamma-ray sterilisation process finalizes the manufacturing cycle of the product. Composition: One iM3 Airgid Small Animal (10 × 10 × 10 mm) contains: Hardened gelatine Ph. Eur. 13.85 mg. Colloid silver Ph. Eur. 0.73 mg. One iM3 Airgid Equine (20 × 20 × 20 mm) contains: Hardened gelatine Ph. Eur. 110.8 mg. Colloid silver Ph. Eur. 5.8 mg. Indications: • Socket extraction as part of one or two-stage implant placement. • The general treatment of alveoli and wound cavities, e.g. after cystostomies, apical amputations, maxillary sinus perforations, following surgical removal of tumours or retained teeth.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • European Patent Office
    Europäisches Patentamt *EP000785714B1* (19) European Patent Office Office européen des brevets (11) EP 0 785 714 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A01N 37/02, A01N 37/04, of the grant of the patent: A01N 37/06, A01N 37/34, 30.08.2000 Bulletin 2000/35 A01N 31/02, A61K 31/19, (21) Application number: 95934953.1 A61K 31/045, A61K 7/48, B27K 3/50, C11D 7/26, (22) Date of filing: 13.10.1995 C11D 7/60 (86) International application number: PCT/SE95/01191 (87) International publication number: WO 96/11572 (25.04.1996 Gazette 1996/18) (54) ANTIMICROBIAL COMPOSITION ANTIMIKROBIELLE ZUSAMMENSETZUNG COMPOSITION ANTIMICROBIENNE (84) Designated Contracting States: • ACTA DERMATO-VENEREOLOGICA, Volume AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL 71, 1991, TUULA KINNUNEN et al., "Antibacterial PT SE and Antifungal Properties of Propylene Glycol, Hexylene Glycol and 1,3 Butylene Glycol in (30) Priority: 14.10.1994 SE 9403541 Vitro", pages 148-150. • ACTA DERMATOVENER, Volume 60, 1980, JAN (43) Date of publication of application: FAERGEMANN et al., "Propylene Glycol in the 30.07.1997 Bulletin 1997/31 Treatment of Tinea Versicolor", pages 92-93. • MARTINDALE W., "The Extra Pharmacopoeia", (73) Proprietor: Moberg, Sven 1977, Twenty-seventh Edition, (London), pages 433 02 Partille (SE) 212, 213, 651, 652, 738-744, 1275-1276. • FOOD CHEMISTRY, Volume 4, No. 4, 1979, G. (72) Inventor: Moberg, Sven POLI et al., "Virucidal Activity of Organic Acids", 433 02 Partille (SE) pages 251-257. • STN INTERNATIONAL, File CA, Chemical (74) Representative: Abstracts, Volume 113, No.
    [Show full text]
  • In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds
    Supplementary Materials In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds Karolina Dydak 1, Adam Junka 1,*, Agata Dydak 2, Malwina Brożyna 1, Justyna Paleczny 1, Karol Fijalkowski 3, Grzegorz Kubielas 4, Olga Aniołek 5 and Marzenna Bartoszewicz 1 1 Department of Pharmaceutical Microbiology and Parasitology, Medical University of Wroclaw, 50-556 Wroclaw, Poland; [email protected] (K.D.); [email protected] (M.B.); [email protected] (J.P.); [email protected] (M.B.) 2 Faculty of Biological Sciences, University of Wroclaw, 51-148 Wroclaw, Poland; [email protected] 3 Department of Microbiology and Biotechnology, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, Szczecin, Piastow 45, 70-311 Szczecin, Poland; [email protected] 4 Faculty of Health Sciences, Wroclaw Medical University, 50-996 Wroclaw, Poland; [email protected] 5 Faculty of Medicine, Lazarski University, 02-662 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-889229341 Citation: Dydak, K.; Junka, A.; Dydak, A.; Brożyna, M.; Paleczny, J.; Abstract: Local administration of antiseptics is required to prevent and fight against biofilm-based Fijalkowski, K.; Kubielas, G.; infections of chronic wounds. One of the methods used for delivering antiseptics to infected wounds Aniołek, O.; Bartoszewicz, M. In is the application
    [Show full text]
  • Avant-Propos Le Format De Présentation De Cette Thèse Correspond À Une Recommandation À La Spécialité
    Avant-propos Le format de présentation de cette thèse correspond à une recommandation à la spécialité Maladies infectieuses, à l’intérieur du Master des Sciences de la Vie et de la Santé qui dépend de l’Ecole Doctorale des Sciences de la Vie de Marseille. Le candidat est amené à respecter les règles qui lui sont imposées et qui comportent un format de thèse utilisé dans le Nord de l’Europe et qui permet un meilleur rangement que les thèses traditionnelles. Par ailleurs, la partie introduction et bibliographie est remplacée par une revue envoyée dans un journal afin de permettre une évaluation extérieure de la qualité de la revue et de permettre à l’étudiant de commencer le plus tôt possible une bibliographie sur le domaine de cette thèse. Par ailleurs, la thèse est présentée sur article publié, accepté, ou soumis associé d’un bref commentaire donnant le sens général du travail. Cette forme de présentation a paru plus en adéquation avec les exigences de la compétition internationale et permet de se concentrer sur des travaux qui bénéficieront d’une diffusion internationale. Professeur Didier RAOULT 2 Remerciements J’adresse mes remerciements aux personnes qui ont contribué à la réalisation de ce travail. En premier lieu, au Professeur Didier RALOUT, qui m’a accueillie au sein de l’IHU Méditerranée Infection. Au Professeur Serge MORAND, au Docteur Marie KEMPF et au Professeur Philippe COLSON de m’avoir honorée en acceptant d’être rapporteurs et examinateurs de cette thèse. Je souhaite particulièrement remercier : Le Professeur Jean-Marc ROLAIN, de m’avoir accueillie dans son équipe et m’avoir orientée et soutenue tout au long de ces trois années de thèse.
    [Show full text]